Axinn partner Chad Landmon was quoted in Christine Livoti's article, "Gilead Could Move to Bundle Recent Idenix Patent Disputes, Likely to Hinge on Issues of Prior Art, Invalidity – Attorneys," which was published January 9 in BioPharm Insight.

Click here to view the article.